Delivery Order SPE2DB22D2206-SPE2DB26FDV60
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Lonsurf (15 mg-6.14 mg tablets, 40-count packages) with a ceiling value of $5,124.17 and firm fixed pricing. This competitively awarded, non-set-aside contract is scheduled for completion by October 17, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $6.76K to AmerisourceBergen Drug Corp for the supply of Lonsurf (20 mg–8.19 mg tablets) in quantities of 40 units. This competitive award, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $5,078.30 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Lonsurf (15 mg-6.14 mg tablets) in quantities of 20 units. This contract represents a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 13, 2025, for the supply of Lonsurf (20 mg–8.19 mg tablets) in a 60-count package with a ceiling value of $10,173.33 under firm fixed-price terms. This is a non-set-aside competitive award with an ultimate completion date of October 3, 2025, and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $10,173.33 to AmerisourceBergen Drug Corp for the supply of Lonsurf (20 mg-8.19 mg tablets, quantity 60) under a firm fixed price contract type. The award, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a non-set-aside competitive procurement. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) designated SPE2DX with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Lonsurf (a cancer treatment medication) in tablet form, with a contract ceiling value of $3,406.92 and an ultimate completion date of November 13, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a continuation...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of LONSURF (20 mg-8.19 mg tablets, 60-count packages) with a ceiling value of $10,173.33. This competitively awarded, non-set-aside contract is scheduled for completion by September 30, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $6,760.14 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Lonsurf (20 mg-8.19 mg tablets) in quantities of 40 units. This is a firm fixed price contract with an ultimate completion date of August 12, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of LONSURF (15 mg-6.14 mg tablets) in a quantity of 40 units, with a ceiling value of $5,124.17 and firm fixed pricing. This delivery order, which is not set-aside, is scheduled for completion by August 28, 2025, with performance occurring at the vendor's location in Conshohocken, Pennsylvania. The award represents a competitive procurement under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LONSURF (20 mg-8.19 mg tablets, 20-count) on October 22, 2025, with a ceiling value of $6,813.86 and an ultimate completion date of November 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's extensive pharmaceutical supply relationship with the federal government. AmerisourceBergen Drug Corp, headquartered...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDV60Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Lonsurf (15 mg-6.14 mg tablets, 40-count packages) valued at $5,124.16. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of November 21, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was competitively selected to fulfill this medical supply requirement through its federal contracting capabilities. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vehicle enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The Lonsurf delivery represents a specific requisition for cancer treatment medication to support the Defense Health Agency and other federal healthcare systems through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 10/30/25 |